|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Matrix Metalloproteinase Inhibitors: Current Developments and Future Perspectives显示文摘 | Hoekstra R Eskens F Verweij J | 2001 | The Oncologist2001，6，5： | 1 |
| 2 | Angiogenesis inhibitors in clinical development; Where are we now and where are we going 显示文摘 | Eskens F | 2004 | British J Cancer2004，90，1： | 1 |
| 3 | Phase I and Pharmacologic Study of PK1166,an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor,in Patients with Advanced Solid Malignancie显示文摘 | Hoekstra R Dumez H Eskens F A | 2005 | Clin Cancer Res2005，11，19： | 1 |
| 4 | Matrix Metalloproteinase Inhibitors:Current Developments and Future Perspectives显示文摘 | HOEKSTRA R ESKENS F VERWEIJ J | 2001 | The Oncologist2001，6，： | 1 |
| 5 | Angiogenesis inhibitors in clinical development: where are we now and where are we going? 显示文摘 | Eskens F | 2004 | Br J Cancer2004，90，1： | 1 |
| 6 | Phase Ⅱ study of neoadjuvant chemotherapy with paclitaxel and cisplatin given every 2 weeks for patients with a respectable squamous cell carcinoma of the oesophagus显示文摘 | Polee M B Tilanus H W Eskens F A | | 0，，08： | 1 |
| 7 | An open-labelphase I dose escalation study of KRN951,a tyrosinekinase inhibitor of vascular endothelial growth factorreceptor 2 and 1 in a 4 week on,2 week off schedule inpatients with advanced solid tumors显示文摘 | Eskens F A Planting A Doorn L V | 2006 | J Clin Oncol2006，24，18： | 1 |
| 8 | Angiiogenesis inhibitors in clinical development; Where are we now and where are we going? 显示文摘 | Eskens F A | 2004 | Br J Cancer2004，90，1： | 1 |
| 9 | Phase I dose escalation study of telatinib,a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2and 3,platelet-derived growth factor receptorβ,and cKit,in patients with advanced or metastatic solid tumors显示文摘 | ESKENS F STEEGHS N VERWEIJ J | 2009 | J Clin Oncol2009，27，25： | 1 |
| 10 | A phase I dose esca-lation study of BIBW 2992,an irreversible dual inhibitor of epider-mal growth factor receptor 1(EGFR)and 2(HER2)tyrosine ki-nase in a 2-week on,2-week off schedule in patients with ad-vanced solid tumours显示文摘 | Eskens F A Mom C H Planting A S | 2008 | Sr J Cancer2008，98，1： | 1 |
| 11 | Phase II study of neo-adjuvant chemotherapy with paclitaxel and cisplatin given every 2 weeks for patients with a resectable squamous cell carcinoma of the esophagus显示文摘 | Polee M B Tilanus H W Eskens F A | | 0，，08： | 1 |
| 12 | Angiogenesis inhibitors in clinical development, where are we now and where are we goingsquest显示文摘 | Eskens F | 2004 | British J cancer2004，90，1： | 1 |
| 13 | Phase I显示文摘 | Polee M B Eskens F A Vander Burg M E | 2002 | Br J Cancer2002，86，5： | 1 |
| 14 | Phase I and pharmacological study ofthe oral matrix metalloproteinase inhibitor, MM1270(CGS27023A), in patientswith advanced solid cancer 显示文摘 | Levitt N C Eskens F A O'Byrne K J | 2001 | Clin Cancer Res2001，7，7： | 1 |
| 15 | Vascular disrupting agents in clinical development显示文摘 | Hinnen P Eskens F A | 2007 | Br J Cancer2007，96，8： | 1 |
| 16 | Phase II study of neoadjuvant chemotherapy with paclitaxel and cisplatin given every 2 weeks for patients with a resectable squamous cell carcinoma of the esophagus显示文摘 | Potee M B Tilanus H W Eskens F A | 2003 | Ann Oncol2003，14，8： | 1 |
| 17 | Phase Ⅱ study of biweekly administration of paditaxel and cisplatin in patients with advanced esophageal cancer 显示文摘 | Polee M B Tilanus HW Eskens F A | 2002 | Br Cancer2002，86，5： | 1 |
| 18 | Angiogenesis inhibitors in clinical development; Where are we now and where are we going 显示文摘 | Eskens F | 2004 | British J Cancer2004，90，1： | 1 |
| 19 | Biologic and clinical activity of tivozanib (AV-951, KRN-951), a selective inhibitor of VEGF receptor-l, -2, and -3 tyrosine kinases, in a 4-week-on, 2-week-off schedule in patients with advanced solid tumors 显示文摘 | Eskens F Jonge M Bhargava P | 2011 | Clin CancerRes2011，17，22： | 1 |
| 20 | Phase study of biweekly administration of paclitaxel and cisplatin in patiens with advanced esophageal cancer显示文摘 | Polee M B Eskens F A Burg M E | 2002 | Br Cancer2002，86，5： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员